{"product_id":"pancreatic-cancer-resectability-after-neoadjuvant-treatment-understanding-the-imaging-challenge","title":"Pancreatic Cancer Resectability After Neoadjuvant Treatment: Understanding the Imaging Challenge","description":"\u003cp\u003eThis review article examines the significant challenge of determining whether pancreatic cancer can be surgically removed after patients receive chemotherapy or radiation before surgery, known as neoadjuvant therapy. Traditional CT scan criteria, particularly the degree of tumor contact with blood vessels, often fail to accurately distinguish between live cancer cells and scar tissue that forms after treatment. The authors found that dynamic changes in how the tumor interacts with blood vessels over time provide better guidance for surgical decisions. Blood markers like CA 19-9 and the patient's overall health also provide better guidance than static imaging measurements alone.\u003c\/p\u003e\n\n\u003ch1\u003ePancreatic Cancer Resectability After Neoadjuvant Treatment: Understanding the Imaging Challenge\u003c\/h1\u003e\n\n\u003ch2\u003eTable of Contents\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"#ddn-key-points\"\u003eKey Points\u003c\/a\u003e\u003c\/li\u003e\n\n\u003cli\u003e\u003ca href=\"#background\"\u003eBackground: Why This Research Matters\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#methods\"\u003eHow This Research Was Conducted\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#key-findings\"\u003eKey Findings: What the Research Revealed\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#arterial-venous\"\u003eArterial vs. Venous Involvement: Different Behaviors\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#imaging-signs\"\u003eNew Imaging Signs of Treatment Response\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#tumor-size\"\u003eWhy Tumor Size Changes Can Be Misleading\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#timing\"\u003eOptimal Timing for Imaging Assessment\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#clinical-implications\"\u003eClinical Implications for Patients\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#limitations\"\u003eLimitations of Current Imaging\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#recommendations\"\u003eRecommendations for Patients and Care Teams\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#ddn-faq\"\u003eFrequently Asked Questions\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#source\"\u003eSource Information\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- ddn:keypoints:start --\u003e\n\u003ch2 id=\"ddn-key-points\"\u003eKey Points\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eAfter neoadjuvant therapy, CT often overestimates vessel involvement because scar tissue can look like tumor; in one study, specificity for R0 resectability fell from about 88% to 52%.\u003c\/li\u003e\n\u003cli\u003eIn one series, only about one-third of artery segments still encased more than 180 degrees on CT had actual cancer invasion of the artery.\u003c\/li\u003e\n\u003cli\u003eIn one study, partial regression of tumor contact with the superior mesenteric or portal vein was linked to R0 resection in 100% of cases.\u003c\/li\u003e\n\u003cli\u003eIn reported series, only about 10% to 15% of patients had tumor shrinkage on CT, yet R0 resection rates among those operated on were often greater than 90%.\u003c\/li\u003e\n\u003cli\u003eA repeat multidetector CT is recommended within 25 days of any planned definitive operation to avoid finding metastatic disease unexpectedly at surgery.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- ddn:keypoints:end --\u003e\n\n\n\u003ch2 id=\"background\"\u003eBackground: Why This Research Matters\u003c\/h2\u003e\n\n\u003cp\u003ePancreatic ductal adenocarcinoma (PDAC), the most common type of pancreatic cancer, remains one of the most challenging cancers to treat. The disease has a rising incidence worldwide and continues to have a poor prognosis. The five-year survival rate remains below 10%, meaning fewer than 1 in 10 patients survive five years after diagnosis.\u003c\/p\u003e\n\n\u003cp\u003eThis poor outcome is primarily due to several factors. Pancreatic cancer tends to spread systemically early in the disease process. The cancer also invades nerves and frequently wraps around major blood vessels. These characteristics limit the number of patients who can undergo surgery that could potentially cure the disease.\u003c\/p\u003e\n\n\u003cp\u003eAt the time of diagnosis, most patients already have locally advanced cancer that has spread to nearby tissues or metastatic disease that has spread to distant organs. For patients with localized tumors that have not spread, surgical removal followed by chemotherapy offers the only potentially curative option. Achieving negative surgical margins, called R0 resection, is critical for long-term survival. This means no cancer cells are found at the edges of the removed tissue.\u003c\/p\u003e\n\n\u003ch3\u003eInitial Imaging and Staging\u003c\/h3\u003e\n\n\u003cp\u003eContrast-enhanced multidetector CT (computed tomography) is the standard imaging method for initially staging pancreatic cancer. Medical teams use classification systems based on pancreatic protocol CT findings to categorize tumors into four groups:\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eResectable:\u003c\/strong\u003e The tumor shows no arterial or significant venous involvement, with clear fat planes around the superior mesenteric artery (SMA), celiac axis, and portal vein (PV)\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBorderline resectable (BRPC):\u003c\/strong\u003e The tumor shows limited vascular involvement, also called vascular abutment, meaning 180 degrees or less of circumferential contact with major arteries or short-segment venous narrowing that may allow vascular resection or reconstruction\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eLocally advanced (LAPC):\u003c\/strong\u003e The tumor shows more extensive involvement, meaning more than 180 degrees of encasement of critical arteries or occlusion of the superior mesenteric vein\/portal vein confluence that cannot be reconstructed, traditionally precluding immediate surgery\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eUnresectable:\u003c\/strong\u003e The tumor has distant metastases or diffuse vascular encasement\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003ePancreatic Protocol CT Technique\u003c\/h3\u003e\n\n\u003cp\u003eHigh-quality multiphasic CT is crucial for optimal tumor detection and blood vessel assessment. A dedicated pancreatic CT protocol typically includes thin-section imaging of 3 millimeters or less with intravenous contrast during two phases. The late arterial phase, also called the pancreatic parenchymal phase, occurs approximately 40 to 50 seconds after injection. The portal venous phase occurs approximately 65 to 70 seconds after injection. Multiplanar reconstructions allow detailed evaluation.\u003c\/p\u003e\n\n\u003cp\u003eThis technique maximizes how prominently the tumor appears. Pancreatic ductal adenocarcinoma classically appears hypoenhancing, meaning it takes up less contrast than normal pancreas tissue. This allows accurate delineation of tumor-vessel interfaces and involvement of surrounding organs and structures. If initial CT images are not acquired using a pancreas protocol, repeating imaging with an appropriate technique is recommended to ensure precise staging. Using proper imaging protocols improves diagnostic accuracy and confidence in determining whether a tumor can be removed surgically.\u003c\/p\u003e\n\n\u003ch3\u003eNeoadjuvant Therapy and the Need to Reassess Resectability\u003c\/h3\u003e\n\n\u003cp\u003eThe introduction of neoadjuvant therapy (NAT) has redefined the treatment plan for patients with borderline resectable and locally advanced pancreatic cancer. NAT includes multiagent chemotherapy with or without radiation before surgery. Neoadjuvant therapy aims to accomplish several goals:\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eShrink tumors to increase the likelihood of complete R0 resection by sterilizing margins\u003c\/li\u003e\n\u003cli\u003eEliminate micrometastatic disease that may not be visible on imaging\u003c\/li\u003e\n\u003cli\u003eAllow only biologically favorable tumors to proceed to surgery\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThere is growing evidence that neoadjuvant therapy can convert initially unresectable or borderline tumors into candidates for curative resection. This is true even when arterial involvement is present, which was once considered a barrier to surgery. Surgical series have reported successful resections of tumors encasing the celiac axis or superior mesenteric artery following robust responses to neoadjuvant therapy. These cases historically would have been considered inoperable.\u003c\/p\u003e\n\n\u003cp\u003eDespite these therapeutic advances, radiologic assessment of treatment response and post-neoadjuvant therapy resectability remains challenging. Therapy-induced fibrosis (scar tissue), necrosis (tissue death), and inflammation can persist as mass-like tissue on imaging. This obscures the distinction between residual tumor and scar-desmoplastic reaction, which is the fibrous tissue that forms around tumors.\u003c\/p\u003e\n\n\u003cp\u003eContrast-enhanced CT remains the primary imaging method for restaging after neoadjuvant therapy, but it has well-recognized limitations. Persistent soft-tissue encasement of more than 180 degrees around arteries or veins, a finding historically equated with unresectability, may actually represent fibrotic desmoplastic reaction rather than viable tumor after treatment.\u003c\/p\u003e\n\n\u003cp\u003eSimilarly, tumor size on CT may not change appreciably despite a major pathological response. This often occurs due to stromal collapse or therapy-related edema (swelling). Conventional radiographic criteria, such as absolute tumor diameter or static degrees of vessel contact, often fail to correlate with histopathologic response following treatment. These limitations underscore the need for a redefined post-neoadjuvant therapy imaging assessment that goes beyond pre-treatment anatomic criteria and incorporates both morphologic and dynamic features.\u003c\/p\u003e\n\n\u003cp\u003eComplementary imaging modalities and techniques are being explored to improve post-therapy evaluation. Perfusion CT, diffusion-weighted MRI (DW-MRI), and PET\/CT can provide functional insights into tumor biology, including vascular perfusion, cellularity, and metabolic activity. These techniques may help distinguish fibrosis from residual tumor.\u003c\/p\u003e\n\n\u003cp\u003eEarly studies have shown that changes in perfusion parameters or ADC values on DW-MRI can correlate with treatment response. PET with 18F-FDG can demonstrate metabolic tumor response that sometimes precedes morphologic change. However, these techniques lack standardized response criteria and can lead to variable results. CT remains the cornerstone of assessment, often supplemented with these modalities. Additionally, evolving surgical strategies, including planned vascular resections and reconstructions, have broadened the surgical candidacy of patients with residual vascular involvement following neoadjuvant therapy.\u003c\/p\u003e\n\n\u003ch2 id=\"methods\"\u003eHow This Research Was Conducted\u003c\/h2\u003e\n\n\u003cp\u003eThe authors performed a comprehensive literature search to examine the evolving imaging criteria used to assess pancreatic cancer resectability following neoadjuvant therapy. They systematically queried the PubMed database for English-language articles published in the last 25 years focusing on post-neoadjuvant therapy radiologic evaluation.\u003c\/p\u003e\n\n\u003cp\u003eSearch terms included combinations of \"pancreatic cancer,\" \"neoadjuvant therapy,\" \"CT,\" \"resectability,\" \"vascular involvement,\" and \"imaging response.\" Both prospective and retrospective studies were included. Relevant meta-analyses and consensus guideline papers were also included.\u003c\/p\u003e\n\n\u003cp\u003eSelection priority was given to studies directly evaluating the accuracy of CT in predicting surgical resectability or pathologic response after neoadjuvant therapy. Priority was also given to studies evaluating other imaging modalities like MRI or PET. Studies dealing with only pre-treatment imaging were excluded. Small case series or single case reports were also excluded to maintain robust evidence.\u003c\/p\u003e\n\n\u003cp\u003eIn total, the authors identified several relevant studies and extracted data on imaging findings such as tumor size and vessel involvement. They also extracted data on how these findings correlated with surgical and pathological outcomes, as well as any proposed new criteria or qualitative signs. These findings were synthesized qualitatively for this narrative review. No formal meta-analysis was performed given the heterogeneity in study designs and endpoints, but consensus trends across the literature were emphasized.\u003c\/p\u003e\n\n\u003ch2 id=\"key-findings\"\u003eKey Findings: What the Research Revealed\u003c\/h2\u003e\n\n\u003cp\u003eThe evidence synthesized from multiple studies reveals a paradigm shift in the radiologic assessment of pancreatic cancer resectability after neoadjuvant therapy. Collectively, these data demonstrate that traditional CT criteria are insufficiently reliable for predicting surgical resectability or true residual tumor status in the post-neoadjuvant therapy setting. These criteria include tumor size and the extent of tumor-vessel contact.\u003c\/p\u003e\n\n\u003cp\u003eA recurring finding is a marked reduction in the specificity of CT for detecting actual tumor invasion of vessels after neoadjuvant therapy. Specificity refers to how well a test correctly identifies patients who do not have the condition. CT frequently overestimates residual tumor involvement of vessels, likely due to the presence of fibrosis following therapy that maintains a mass effect or encasement appearance.\u003c\/p\u003e\n\n\u003ch3\u003eSpecific Study Results\u003c\/h3\u003e\n\n\u003cp\u003eIn a study by Cassinotto and colleagues, the specificity of CT for R0 resectability dropped from approximately 88% before therapy to approximately 52% after neoadjuvant therapy. CT often overcalled vascular invasion that was not found at surgery. The researchers noted that 12 of 31 patients who achieved complete R0 resection after neoadjuvant therapy had been interpreted as \"high risk of incomplete resection\" on restaging CT. This interpretation was due to apparent vascular involvement.\u003c\/p\u003e\n\n\u003cp\u003eSimilarly, White and colleagues observed that restaging CT after chemoradiation tended to overstage disease. This excluded some patients from surgery who actually could have undergone R0 resection. These findings underscore that using static pre-treatment CT cutoffs, such as more than 180 degrees of arterial encasement, in the post-treatment context will often underestimate resectability.\u003c\/p\u003e\n\n\u003cp\u003eA particularly illustrative result comes from Mayer and colleagues, who specifically evaluated arterial encasement greater than 180 degrees in post-neoadjuvant therapy CT. They found that only approximately one-third of arterial segments that still appeared encased more than 180 degrees on CT had actual histologic tumor invasion of the artery. In their series, many patients with persistent circumferential arterial contact on CT were nevertheless able to undergo successful R0 resections.\u003c\/p\u003e\n\n\u003cp\u003eThis suggests that a substantial proportion of what looks like artery encasement after therapy is actually due to desmoplastic reaction or inflammatory tissue rather than viable cancer.\u003c\/p\u003e\n\n\u003ch3\u003eVenous Involvement Findings\u003c\/h3\u003e\n\n\u003cp\u003eThe same appears true for veins. Multiple studies reported that persistent vein narrowing or occlusion on CT after neoadjuvant therapy does not always signify unresectability. The vein can often be safely resected or even found patent at surgery with only fibrous adhesions remaining.\u003c\/p\u003e\n\n\u003cp\u003eCassinotto and colleagues noted that even when the superior mesenteric vein (SMV) or portal vein remained stenosed on post-therapy CT, this finding was not predictive of an R1 resection. R1 resection means cancer cells are found at the margin of the removed tissue. In their cohort, vein narrowing often did not equate to residual tumor at the margin.\u003c\/p\u003e\n\n\u003cp\u003eIn contrast, when they did observe any partial regression of the tumor-vessel interface on CT, it was a very positive sign. This was true even if the vessel was still contacted but to a lesser degree or over a shorter length. Partial regression of tumor contact with the superior mesenteric vein or portal vein was associated with R0 resection in 100% of cases in that study. Partial regression of contact with any major vessel, whether arterial or venous, predicted R0 resection in 91% of cases.\u003c\/p\u003e\n\n\u003cp\u003eThese statistics highlight how changes in the tumor-vessel interface are more prognostically meaningful than the static presence of contact itself.\u003c\/p\u003e\n\n\u003ch2 id=\"arterial-venous\"\u003eArterial vs. Venous Involvement: Different Behaviors\u003c\/h2\u003e\n\n\u003cp\u003ePost-neoadjuvant therapy imaging interpretation must distinguish between arterial and venous responses because they behave differently.\u003c\/p\u003e\n\n\u003ch3\u003eArterial Involvement\u003c\/h3\u003e\n\n\u003cp\u003eCT signs such as more than 180 degrees of encasement are no longer definitive for unresectability. Desmoplastic tissue may encase arteries without actual invasion. Studies suggest that partial or incomplete arterial contact after neoadjuvant therapy is often resectable, especially if accompanied by halo signs or preserved vessel contour.\u003c\/p\u003e\n\n\u003ch3\u003eVenous Involvement\u003c\/h3\u003e\n\n\u003cp\u003eVeins such as the superior mesenteric vein and portal vein frequently recanalize after neoadjuvant therapy. Recanalization means the vein opens up again. Persistent occlusion may still be surgically manageable. The restoration of patency or improved caliber is a strong indicator of treatment response. Persistent narrowing alone is not predictive of R1 resections and should not preclude exploration.\u003c\/p\u003e\n\n\u003ch2 id=\"imaging-signs\"\u003eNew Imaging Signs of Treatment Response\u003c\/h2\u003e\n\n\u003cp\u003eAnother key observation across the literature is that qualitative changes in perivascular tissue and vessel patency on CT correlate better with outcomes than do gross tumor size changes. Zins and colleagues have emphasized that simple metrics like tumor diameter or even CT attenuation change have poor correlation with pathologic response or tumor resectability.\u003c\/p\u003e\n\n\u003cp\u003eInstead, radiologists are noting several features as more indicative of a favorable response:\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eReduction in the circumferential degree of vessel contact\u003c\/li\u003e\n\u003cli\u003eRestoration of a normal vessel contour or lumen caliber\u003c\/li\u003e\n\u003cli\u003eDevelopment of a perivascular hypoattenuating \"halo\" replacing what was previously solid tumor around a vessel\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eThe Halo Sign\u003c\/h3\u003e\n\n\u003cp\u003eThe \"halo sign\" refers to the appearance of a low-density rim between the tumor and vessel on post-neoadjuvant therapy CT where previously the tumor was in direct contact. This is essentially an ill-defined fatty or scar tissue plane enveloping the vessel. Its appearance has been linked with tumor regression and the potential for a safe dissection plane surgically.\u003c\/p\u003e\n\n\u003cp\u003eIn one series, the presence of a low-contrast perivascular halo of approximately 46 Hounsfield units or less adjacent to an artery was identified. This was the unique CT feature distinguishing cases where the artery was not truly invaded. Hounsfield units are a measure of density on CT scans.\u003c\/p\u003e\n\n\u003ch2 id=\"tumor-size\"\u003eWhy Tumor Size Changes Can Be Misleading\u003c\/h2\u003e\n\n\u003cp\u003eImportantly, even cases without vast radiologic tumor shrinkage can still be resectable. Several studies documented that objective RECIST partial responses on imaging are relatively uncommon with neoadjuvant therapy. RECIST stands for Response Evaluation Criteria in Solid Tumors, a standard way to measure tumor shrinkage. Often, the majority of cases are radiologically \"stable disease,\" meaning the tumor size has not changed significantly.\u003c\/p\u003e\n\n\u003cp\u003eYet a substantial subset of these patients still achieve R0 resections and major pathologic tumor clearance. Marthey and colleagues and Xia and colleagues reported on borderline and locally advanced pancreatic cancer patients who completed neoadjuvant therapy and went to surgery. Only approximately 10% to 15% of these patients showed partial tumor shrinkage on CT. Approximately 70% had stable disease by size criteria.\u003c\/p\u003e\n\n\u003cp\u003eDespite this, R0 resection rates in these surgical patients were high, often greater than 90% in responders. This indicates that the lack of a radiologic tumor size reduction does not equate to the lack of a treatment effect. Histopathologically, many of these \"stable disease\" tumors have extensive fibrosis or treatment-induced necrosis, explaining why they remained radiologically unchanged in size.\u003c\/p\u003e\n\n\u003cp\u003eThe meta-analysis of Suker and colleagues noted that many patients with stable or minimal response on imaging following neoadjuvant therapy with FOLFIRINOX still underwent successful resections. FOLFIRINOX is a combination chemotherapy regimen used for pancreatic cancer.\u003c\/p\u003e\n\n\u003ch3\u003eMeta-Analysis Results\u003c\/h3\u003e\n\n\u003cp\u003eSimilar findings come from larger meta-analyses and series. A pooled analysis by Gillen and colleagues found that neoadjuvant therapy enabled surgical resection in roughly 26% of patients with initially unresectable or borderline tumors. The overall R0 resection rate was approximately 77% among those resected.\u003c\/p\u003e\n\n\u003cp\u003eMore recent multi-institution studies, such as those by Ferrone and colleagues, report even higher conversion rates. In Ferrone's series, approximately 30% of locally advanced pancreatic cancer patients were ultimately resected after FOLFIRINOX. Remarkably, 92% of those who reached the operating table had an R0 resection.\u003c\/p\u003e\n\n\u003cp\u003eNotably, the majority, approximately 70%, of Ferrone's patients still had tumors appearing \"borderline or unresectable\" on post-neoadjuvant therapy CT. This underscores how imaging often did not reflect the true resectability that became evident intraoperatively. In their cohort, nearly half of the patients deemed unresectable by imaging after neoadjuvant therapy were found to be resectable at surgery, with successful margin-negative outcomes in most.\u003c\/p\u003e\n\n\u003cp\u003eThese outcomes collectively reinforce the idea that persistent CT findings of vessel involvement after neoadjuvant therapy, especially venous involvement, should not be viewed as an absolute contraindication to exploration. Instead, a comprehensive evaluation should guide the decision of whether to proceed to operation. This evaluation should incorporate interval imaging changes rather than static findings, tumor marker dynamics such as CA 19-9 drop, and clinical status.\u003c\/p\u003e\n\n\u003ch2 id=\"timing\"\u003eOptimal Timing for Imaging Assessment\u003c\/h2\u003e\n\n\u003cp\u003eThe optimal timing for imaging assessment after pancreatic cancer treatment depends on the treatment type and the specific goals of the imaging. Generally, imaging is performed 3 to 6 months after treatment to assess response and detect recurrence.\u003c\/p\u003e\n\n\u003cp\u003eHowever, for patients with resectable disease, imaging may be performed closer to the surgical date. Patients undergoing neoadjuvant therapy may have imaging scans conducted more frequently to monitor treatment response.\u003c\/p\u003e\n\n\u003cp\u003ePatients should undergo a repeat multidetector CT within 25 days of any planned definitive operative intervention for pancreatic cancer. This helps avoid unexpectedly finding metastatic disease at surgery.\u003c\/p\u003e\n\n\u003ch2 id=\"clinical-implications\"\u003eClinical Implications for Patients\u003c\/h2\u003e\n\n\u003cp\u003eThe findings of this review have several important implications for patients with pancreatic cancer considering surgery after neoadjuvant therapy.\u003c\/p\u003e\n\n\u003ch3\u003eImaging Alone Should Not Determine Surgical Candidacy\u003c\/h3\u003e\n\n\u003cp\u003ePersistent vessel contact on CT after neoadjuvant therapy does not necessarily mean a patient cannot have surgery. Many patients with what appears to be persistent vascular involvement on imaging are still able to undergo successful complete resections. The imaging findings often represent scar tissue rather than active cancer.\u003c\/p\u003e\n\n\u003ch3\u003eChanges Over Time Matter More Than Static Findings\u003c\/h3\u003e\n\n\u003cp\u003eHow the tumor-vessel relationship changes between scans is more important than any single snapshot. Partial regression of tumor contact with blood vessels, even if some contact remains, is a strong predictor of successful complete resection. Patients should discuss with their care team how their imaging findings have evolved over time.\u003c\/p\u003e\n\n\u003ch3\u003eMultiple Factors Guide Surgical Decisions\u003c\/h3\u003e\n\n\u003cp\u003eThe decision to proceed with surgery after neoadjuvant therapy should incorporate multiple factors beyond imaging alone:\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eInterval changes on imaging rather than static findings\u003c\/li\u003e\n\u003cli\u003eTumor marker dynamics, such as a significant drop in CA 19-9 levels\u003c\/li\u003e\n\u003cli\u003ePatient performance status and overall fitness for surgery\u003c\/li\u003e\n\u003cli\u003eAbsence of metastatic disease\u003c\/li\u003e\n\u003cli\u003eInput from a multidisciplinary team including surgeons, radiologists, oncologists, and pathologists\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eThe Role of Multidisciplinary Assessment\u003c\/h3\u003e\n\n\u003cp\u003eA collaborative decision-making process that incorporates clinical findings, imaging results, laboratory data, patient comorbidities, and preferences is essential. This process typically involves input from surgeons, radiologists, oncologists, pathologists, and other relevant specialists to ensure a well-rounded and individualized treatment plan.\u003c\/p\u003e\n\n\u003cp\u003eRadiologic findings should be considered alongside serum tumor markers. For example, a dramatic drop in CA 19-9 strengthens the argument that a radiologically static mass may be largely fibrotic. The patient's overall condition also matters.\u003c\/p\u003e\n\n\u003cp\u003eSurgeons experienced in pancreatic cancer should be directly involved in imaging review. Sometimes a surgeon may judge that even though a vessel looks involved, they have strategies to handle it. This is especially true if other indicators like lack of metastases and patient fitness are favorable.\u003c\/p\u003e\n\n\u003cp\u003eThe decision to proceed to surgery after neoadjuvant therapy often comes down to whether there is any chance for R0 resection and no evidence of metastatic disease. Given the disconnect between radiographic appearance and pathologic reality in many cases, tumor boards increasingly err on the side of surgical exploration. This occurs if imaging is equivocal but other factors are encouraging. This approach has led to improved outcomes for some patients who previously would have been deemed unresectable from imaging alone.\u003c\/p\u003e\n\n\u003ch2 id=\"limitations\"\u003eLimitations of Current Imaging\u003c\/h2\u003e\n\n\u003cp\u003eDespite improvements in understanding, post-neoadjuvant therapy imaging faces inherent limitations. CT cannot reliably distinguish live tumor cells from fibrotic tissue on a microscopic level. Some patients will have residual microscopic cancer in areas that appear \"clean\" on CT, leading to positive margins or early recurrence despite favorable imaging.\u003c\/p\u003e\n\n\u003cp\u003eConversely, CT can also underestimate response in some cases. For instance, a treated tumor may not shrink much but could be mostly necrotic. Unless there are calcifications or obvious necrotic patterns, CT might label it as stable disease when it has actually responded well to treatment.\u003c\/p\u003e\n\n\u003cp\u003eThese limitations mean that imaging is one piece of the puzzle rather than the complete answer. Ongoing research into imaging biomarkers and the adoption of advanced analytics hold promise for closing the gap between radiographic assessment and the ground truth of tumor viability.\u003c\/p\u003e\n\n\u003ch2 id=\"recommendations\"\u003eRecommendations for Patients and Care Teams\u003c\/h2\u003e\n\n\u003cp\u003eBased on this comprehensive review, several recommendations emerge for patients with pancreatic cancer undergoing neoadjuvant therapy and their care teams.\u003c\/p\u003e\n\n\u003ch3\u003eFor Patients\u003c\/h3\u003e\n\n\u003col\u003e\n\u003cli\u003eUnderstand that imaging findings after neoadjuvant therapy do not always reflect the true status of your cancer. Persistent vessel contact on CT may represent scar tissue rather than active cancer.\u003c\/li\u003e\n\u003cli\u003eAsk your care team to explain how your imaging findings have changed over time, not just what the current scan shows.\u003c\/li\u003e\n\u003cli\u003eDiscuss your CA 19-9 levels and how they have changed during treatment, as this blood marker provides additional information about treatment response.\u003c\/li\u003e\n\u003cli\u003eEnsure your case is reviewed by a multidisciplinary tumor board with experience in pancreatic cancer before final decisions about surgery are made.\u003c\/li\u003e\n\u003cli\u003eSeek care at a center with experienced pancreatic cancer surgeons who can evaluate whether surgery is feasible even when imaging appears concerning.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003ch3\u003eFor Care Teams\u003c\/h3\u003e\n\n\u003col\u003e\n\u003cli\u003eTransition from static morphologic criteria to response-based interpretation when assessing resectability after neoadjuvant therapy.\u003c\/li\u003e\n\u003cli\u003eFocus on interval changes in tumor-vessel relationships rather than absolute thresholds.\u003c\/li\u003e\n\u003cli\u003eRecognize the halo sign and vessel contour restoration as favorable indicators of treatment response.\u003c\/li\u003e\n\u003cli\u003eConsider venous involvement differently from arterial involvement, as veins frequently recanalize and persistent narrowing alone should not preclude exploration.\u003c\/li\u003e\n\u003cli\u003eIntegrate radiologic, biochemical, and clinical findings in multidisciplinary evaluation to guide surgical decision-making.\u003c\/li\u003e\n\u003cli\u003eEnsure repeat multidetector CT within 25 days of any planned definitive operative intervention.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003eIn summary, post-neoadjuvant imaging requires a paradigm shift in interpretation. Radiologists must embrace a more dynamic assessment, noting how tumor-vessel relationships have changed rather than just whether they are present. Understanding the differences in arterial and venous responses and recognizing signs like the halo can provide critical guidance. However, imaging is one piece of the puzzle. The integration of multiple factors through multidisciplinary evaluation is essential to guide surgical decision-making and improve patient outcomes.\u003c\/p\u003e\n\n\u003c!-- ddn:faq:start --\u003e\n\u003ch2 id=\"ddn-faq\"\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eIf my CT still shows the tumor touching a blood vessel after chemotherapy, does that mean I can't have surgery?\u003c\/h3\u003e\n\u003cp\u003eNot necessarily. In one study, only about one-third of artery segments that still looked encased more than 180 degrees on CT had actual cancer invasion. Much of what looks like vessel involvement after treatment is scar tissue, so persistent contact alone should not rule out surgery.\u003c\/p\u003e\n\u003ch3\u003eWhy does my scan report say 'stable disease' when the treatment is supposed to be working?\u003c\/h3\u003e\n\u003cp\u003eTumor size often does not shrink much even when treatment works. In reported series, only about 10% to 15% of patients showed partial shrinkage on CT, while about 70% had stable disease by size. Many of these tumors were mostly scar or dead tissue, and R0 resection rates were still high.\u003c\/p\u003e\n\u003ch3\u003eWhat does a drop in my CA 19-9 level mean for my chances of surgery?\u003c\/h3\u003e\n\u003cp\u003eCA 19-9 is a blood marker that adds information beyond imaging. A significant drop strengthens the argument that a mass that looks unchanged on CT may be largely scar tissue rather than active cancer. It should be considered alongside your scans, fitness for surgery, and multidisciplinary review.\u003c\/p\u003e\n\u003ch3\u003eWhat is the halo sign on a CT scan after treatment?\u003c\/h3\u003e\n\u003cp\u003eThe halo sign is a low-density rim seen between the tumor and a blood vessel after treatment, where the tumor was previously in direct contact. It is thought to be a scar or fatty tissue plane. In one series, a perivascular halo of about 46 Hounsfield units or less distinguished arteries that were not truly invaded.\u003c\/p\u003e\n\u003ch3\u003eHow soon before surgery should I have another CT scan?\u003c\/h3\u003e\n\u003cp\u003eA repeat multidetector CT should be done within 25 days of any planned definitive operation for pancreatic cancer. This helps avoid unexpectedly finding metastatic disease at the time of surgery. Imaging after treatment is generally performed 3 to 6 months afterward, or more often during neoadjuvant therapy.\u003c\/p\u003e\n\u003ch3\u003eWho decides whether I go to surgery after neoadjuvant therapy?\u003c\/h3\u003e\n\u003cp\u003eA multidisciplinary team should decide, including surgeons, radiologists, oncologists, and pathologists. The decision should weigh interval changes on imaging rather than one snapshot, tumor marker trends such as CA 19-9, your performance status, absence of metastatic disease, and your preferences. Imaging alone should not determine surgical candidacy.\u003c\/p\u003e\n\u003ch3\u003eCan a vein that is still narrowed or blocked after treatment still be removed surgically?\u003c\/h3\u003e\n\u003cp\u003eOften yes. Multiple studies found that persistent narrowing or blockage of the superior mesenteric vein or portal vein on CT after neoadjuvant therapy does not always mean the cancer cannot be removed. Veins frequently reopen after treatment, and persistent narrowing alone was not predictive of a positive margin.\u003c\/p\u003e\n\u003ch3\u003eMy pancreatic tumor still looks like it's touching a major blood vessel after chemotherapy — should I get a second opinion before accepting that surgery isn't possible?\u003c\/h3\u003e\n\u003cp\u003eYes. Persistent vessel contact on CT after neoadjuvant therapy often represents scar tissue rather than active cancer. Only about one-third of arterial segments still appearing encased beyond 180 degrees had true tumor invasion, and many patients with persistent contact still achieved complete R0 resections. Partial regression of tumor-vessel contact predicted R0 resection in 91% of cases. Because imaging frequently overestimates residual involvement, a review of how your scans changed over time, alongside CA 19-9 trends and multidisciplinary input, can clarify whether surgery remains feasible. Diagnostic Detectives Network provides independent expert second opinions.\u003c\/p\u003e\n\u003c!-- ddn:faq:end --\u003e\n\n\u003ch2 id=\"source\"\u003eSource Information\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eOriginal Article Title:\u003c\/strong\u003e Pancreatic Cancer Resectability After Neoadjuvant Treatment: An Imaging Challenge.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eJournal:\u003c\/strong\u003e Diagnostics (Basel, Switzerland)\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eLicense:\u003c\/strong\u003e CC BY (open access)\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eAuthors:\u003c\/strong\u003e Christofilis I, Triantopoulou C, Delis S.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eAuthor Affiliations:\u003c\/strong\u003e Radiology Department, Konstantopouleio Hospital, Athens, Greece; HPB Unit, Konstantopouleio Hospital, Athens, Greece\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003ePublication:\u003c\/strong\u003e Diagnostics 2025, Volume 15, Article 1810\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003ePublication Date:\u003c\/strong\u003e Published July 18, 2025\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eDOI:\u003c\/strong\u003e https:\/\/doi.org\/10.3390\/diagnostics15141810\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eAcademic Editor:\u003c\/strong\u003e Antonio Facciorusso\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eArticle Type:\u003c\/strong\u003e Review\u003c\/p\u003e\n\n\u003cp\u003e\u003cem\u003eThis patient-friendly article is based on peer-reviewed research. The original article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.\u003c\/em\u003e\u003c\/p\u003e","brand":"DiagnosticDetectives.Com","offers":[{"title":"Default Title","offer_id":47816842379420,"sku":null,"price":0.0,"currency_code":"KRW","in_stock":true}],"url":"https:\/\/diagnosticdetectives.kr\/products\/pancreatic-cancer-resectability-after-neoadjuvant-treatment-understanding-the-imaging-challenge","provider":"DiagnosticDetectives.Com","version":"1.0","type":"link"}